Galena Biopharma Inc. (Nasdaq: GALE) will discontinue its Phase 3 PRESENT clinical trial due to futility. Shares of the biopharmaceutical plummeted $1.68 to close at $0.35.
Galena halts clinical trial
June 29, 2016 at 16:51 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|